再発性急性骨髄性白血病(Relapsed Acute Myeloid Leukemia)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Relapsed Acute Myeloid Leukemia Overview 9
Therapeutics Development 10
Pipeline Products for Relapsed Acute Myeloid Leukemia – Overview 10
Pipeline Products for Relapsed Acute Myeloid Leukemia – Comparative Analysis 11
Relapsed Acute Myeloid Leukemia – Therapeutics under Development by Companies 12
Relapsed Acute Myeloid Leukemia – Therapeutics under Investigation by Universities/Institutes 17
Relapsed Acute Myeloid Leukemia – Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Relapsed Acute Myeloid Leukemia – Products under Development by Companies 21
Relapsed Acute Myeloid Leukemia – Products under Investigation by Universities/Institutes 25
Relapsed Acute Myeloid Leukemia – Companies Involved in Therapeutics Development 26
4SC AG 26
AbbVie Inc. 27
Actinium Pharmaceuticals, Inc. 28
Agios Pharmaceuticals, Inc. 29
Amgen Inc. 30
Array BioPharma Inc. 31
Astellas Pharma Inc. 32
Astex Pharmaceuticals, Inc. 33
AstraZeneca PLC 34
AVEO Pharmaceuticals, Inc. 35
Boehringer Ingelheim GmbH 36
Bristol-Myers Squibb Company 37
Calithera Biosciences, Inc. 38
Celgene Corporation 39
Conkwest, Inc. 40
Cornerstone Pharmaceuticals, Inc. 41
CTI BioPharma Corp. 42
Daiichi Sankyo Company, Limited 43
Eisai Co., Ltd. 44
EpiZyme, Inc. 45
Exelixis, Inc. 46
F. Hoffmann-La Roche Ltd. 47
Fujifilm Corporation 48
GlaxoSmithKline plc 49
Igenica Biotherapeutics, Inc. 50
Incyte Corporation 51
Jiangsu Hansoh Pharmaceutical Co., Ltd. 52
JW Pharmaceutical Corporation 53
Karyopharm Therapeutics, Inc. 54
Kyowa Hakko Kirin Co., Ltd. 55
Les Laboratoires Servier SAS 56
MacroGenics, Inc. 57
Merck & Co., Inc. 58
Millennium Pharmaceuticals, Inc. 59
Novartis AG 60
Oxford BioTherapeutics Ltd 61
Plexxikon Inc. 62
Polaris Pharmaceuticals, Inc. 63
Seattle Genetics, Inc. 64
Sunesis Pharmaceuticals, Inc. 65
Synta Pharmaceuticals Corp. 66
Tolero Pharmaceuticals, Inc. 67
Verastem, Inc. 68
Relapsed Acute Myeloid Leukemia – Therapeutics Assessment 69
Assessment by Monotherapy Products 69
Assessment by Combination Products 70
Assessment by Target 71
Assessment by Mechanism of Action 75
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
4SC-202 – Drug Profile 82
AG-120 – Drug Profile 84
AG-221 – Drug Profile 86
alvocidib hydrochloride – Drug Profile 89
AMG-232 – Drug Profile 90
AT-9283 – Drug Profile 91
BI-836858 – Drug Profile 93
binimetinib – Drug Profile 94
bortezomib – Drug Profile 99
brentuximab vedotin – Drug Profile 104
cabozantinib s-malate – Drug Profile 109
cafusertib hydrochloride – Drug Profile 112
CB-839 – Drug Profile 113
Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia – Drug Profile 114
Cell Therapy to Target CD33 for Acute Myeloid Leukemia – Drug Profile 115
Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies – Drug Profile 116
CPI-613 – Drug Profile 117
crenolanib besylate – Drug Profile 119
CST-101 – Drug Profile 121
CWP-291 – Drug Profile 123
DFP-10917 – Drug Profile 125
DS-3032 – Drug Profile 126
elesclomol – Drug Profile 127
EPZ-5676 – Drug Profile 129
erlotinib hydrochloride – Drug Profile 131
FF-10501 – Drug Profile 134
ficlatuzumab – Drug Profile 135
FLX-925 – Drug Profile 137
gilteritinib fumarate – Drug Profile 138
GO-2032c – Drug Profile 139
GSK-2879552 – Drug Profile 140
GSK-525762 – Drug Profile 141
huCART19 – Drug Profile 142
IGN-523 – Drug Profile 143
ilorasertib – Drug Profile 144
imatinib mesylate – Drug Profile 146
indisulam – Drug Profile 148
Iomab-B – Drug Profile 149
KHK-2823 – Drug Profile 151
lenalidomide – Drug Profile 152
LGH-447 – Drug Profile 156
MGD-006 – Drug Profile 157
MK-2206 – Drug Profile 158
OX-001 – Drug Profile 161
pegargiminase – Drug Profile 162
PLX-3397 – Drug Profile 165
quizartinib dihydrochloride – Drug Profile 167
RG-7775 – Drug Profile 170
ruxolitinib phosphate – Drug Profile 171
S-055746 – Drug Profile 176
selinexor – Drug Profile 177
selumetinib sulfate – Drug Profile 181
Small Molecules to Inhibit MDM2 for Oncology – Drug Profile 184
TAK-659 – Drug Profile 185
TEN-010 – Drug Profile 186
tigecycline – Drug Profile 187
tosedostat – Drug Profile 188
trametinib dimethyl sulfoxide + uprosertib – Drug Profile 190
ulocuplumab – Drug Profile 192
venetoclax – Drug Profile 194
vorinostat – Drug Profile 197
vosaroxin – Drug Profile 201
VS-4718 – Drug Profile 203
Relapsed Acute Myeloid Leukemia – Recent Pipeline Updates 204
Relapsed Acute Myeloid Leukemia – Dormant Projects 316
Relapsed Acute Myeloid Leukemia – Discontinued Products 317
Relapsed Acute Myeloid Leukemia – Product Development Milestones 318
Featured News & Press Releases 318
Appendix 326
Methodology 326
Coverage 326
Secondary Research 326
Primary Research 326
Expert Panel Validation 326
Contact Us 326
Disclaimer 327